Andrés Chang
YOU?
Author Swipe
View article: 552 | BRUTON'S TYRONSINE KINASE INHIBITORS VERSUS VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: A RETROSPECTIVE REAL‐WORLD ANALYSIS.
552 | BRUTON'S TYRONSINE KINASE INHIBITORS VERSUS VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: A RETROSPECTIVE REAL‐WORLD ANALYSIS. Open
View article: In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients
In the time of COVID-19: challenges, successes, and lessons learned from studies in cancer patients Open
The COVID-19 pandemic created the urgent need to monitor risk of SARS-CoV-2 infection and mortality and to evaluate immune responses to novel vaccines. A foremost concern was the unknown risks to patients with cancer, considering their ove…
View article: Immunogenic Cell Death: the Key to Unlocking the Potential for Combined Radiation and Immunotherapy
Immunogenic Cell Death: the Key to Unlocking the Potential for Combined Radiation and Immunotherapy Open
Immunogenic cell death (ICD) enhances anti-tumor immunity by releasing tumor-associated antigens and activating the anti-tumor immune system response. However, its potential remains understudied in combination therapies. Here, we develop a…
View article: PANAMÁ EN TRANSICIÓN HACIA UN MODELO SOSTENIBLE: LA ECONOMÍA CIRCULAR COMO UNA ALTERNATIVA
PANAMÁ EN TRANSICIÓN HACIA UN MODELO SOSTENIBLE: LA ECONOMÍA CIRCULAR COMO UNA ALTERNATIVA Open
El artículo aborda la transición de Panamá hacia un modelo sostenible a través de la implementación de la economía circular. Se realizó una revisión bibliográfica y un análisis crítico de los artículos seleccionados, así como la consulta d…
View article: BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer Open
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interest…
View article: CARACTERIZACIÓN DEL PAPEL DEL EQUINO Y SU BIENESTAR EN LA COMUNIDAD RURAL EN PANAMÁ
CARACTERIZACIÓN DEL PAPEL DEL EQUINO Y SU BIENESTAR EN LA COMUNIDAD RURAL EN PANAMÁ Open
El equino desempeña un papel fundamental para el bienestar y la economía de la comunidad rural panameña. Para caracterizar el rol que desempeñan estos animales, la FUCAEP llevó a cabo una encuesta con 500 familias rurales en 2019, que incl…
View article: Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 1. Anti-nucleocapsid IgG and spike IgM titers in NHL/CLL patients.
View article: Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 5. Reduced IgG binding titers against the spike protein of SARS-CoV-2 variants in NHL/CLL patients.
View article: Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 5. Reduced IgG binding titers against the spike protein of SARS-CoV-2 variants in NHL/CLL patients.
View article: Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 3. Kinetics of serologic response after booster vaccination.
View article: Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM r…
View article: Supplementary Table ST3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplementary Table 3. Univariate analyses of clinical variables associated with booster response
View article: Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 3. Kinetics of serologic response after booster vaccination.
View article: Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM r…
View article: Supplementary Table ST2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Table 2. Clinical characteristics of NHL/CLL patients with high anti-spike IgG titers prior to booster vaccination
View article: Supplementary Table ST2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Table 2. Clinical characteristics of NHL/CLL patients with high anti-spike IgG titers prior to booster vaccination
View article: Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 1. Anti-nucleocapsid IgG and spike IgM titers in NHL/CLL patients.
View article: Supplementary Figure SF4 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF4 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 4. Anti-spike binding IgG titers after booster correlate with conventional B cell numbers in the blood prior booster.
View article: Supplementary Table ST3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplementary Table 3. Univariate analyses of clinical variables associated with booster response
View article: Supplementary Figure SF2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 2. Positive correlations in antibody binding titers between anti-Spike IgG and anti-RBD, anti-NTD IgG, and anti-spike IgA and IgM
View article: Supplementary Figure SF4 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF4 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 4. Anti-spike binding IgG titers after booster correlate with conventional B cell numbers in the blood prior booster.
View article: Supplementary Table ST1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Table 1. Clinical and vaccination characteristics of NHL/CLL patients in this study
View article: Supplementary Table ST1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Table ST1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Table 1. Clinical and vaccination characteristics of NHL/CLL patients in this study
View article: Supplementary Figure SF2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF2 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 2. Positive correlations in antibody binding titers between anti-Spike IgG and anti-RBD, anti-NTD IgG, and anti-spike IgA and IgM
View article: Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies Open
To investigate the neutralizing activity of full dose AZD7442 against live, contemporary Omicron variants after administration to patients who are immunocompromised.
View article: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Open
View article: Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Open
View article: Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant Open
PURPOSE To examine COVID-19 mRNA vaccine–induced binding and neutralizing antibody responses in patients with non–small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose an…
View article: Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma Open
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serolog…
View article: Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern Open
Purpose We investigated SARS-CoV-2 mRNA vaccine-induced binding and live-virus neutralizing antibody response in NSCLC patients to the SARS-CoV-2 wild type strain and the emerging Delta and Omicron variants. Methods 82 NSCLC patients and 5…